Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy

CONCLUSION: Our models predicted greater reductions in the occurrence of relapsed mBC with adjuvant T-DM1 vs trastuzumab in the indicated populations in EU5 and Canada. Introduction of T-DM1 has the potential to reduce population-level disease burden of HER2-positive mBC in the geographies studied.PMID:37907759 | DOI:10.1007/s12282-023-01514-w

Source: Breast Cancer - November 1, 2023 Category: Cancer & Oncology Authors: Mellissa Williamson David J Press Svenn Alexander Hansen Akanksha Tomar Gurleen Singh Jhuti Cedric Revil Kaustubh Gururaj Source Type: research